BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City. The presentations will be available on the company website, www.biotimeinc.com. Thomas Okarma, M.D., Ph.D., President and CEO of Asterias Biotherapeutics Inc., will present a summary of Asterias, a new subsidiary of BioTime. Asterias recently acquired Geron Corporation’s human embryonic stem cell assets, as well as certain assets from BioTime, including rights to use certain human embryonic stem cell lines developed by BioTime’s subsidiary ES Cell International Pte Ltd., minority stakes in two of BioTime’s other subsidiaries, and BioTime common shares. William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an update on the development of Renevia™. In his presentation, Dr. Tew will announce that enrollment in a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, is complete and the initial ten subjects who each received one subcutaneous injection of Renevia™ have been followed for three weeks after treatment and to date, Renevia™ has been well-tolerated by all patients with no serious adverse events. BioTime will also describe new work using BioTime’s HyStem ® technology to develop 3D cell culture platforms for improved methods of screening new anti-cancer drug candidates in a project funded by a research grant from the National Institutes of Health. Charles S. Irving, Ph.D., the CEO of BioTime’s subsidiary Cell Cure Neurosciences Ltd. will provide an update on the development of OpRegen ®. In his presentation, Dr. Irving will describe the unmet medical needs and markets for the treatment of the dry form of age-related macular degeneration (AMD), and the advantages of Cell Cure’s OpRegen ® which has been produced from human embryonic stem cells in culture conditions free of animal products, eliminating the need for designating the product as a xenotransplantation therapeutic. Dr. Irving’s presentation will contain assessments of Cell Cure’s approach by key opinion leaders in the fields of macular degeneration and human embryonic stem cell research. Dr. Irving will describe the progress of the ongoing preclinical studies which are expected to lead to regulatory filings for the initiation of human clinical trials in 2014. Joe Wagner, Ph.D., the CEO of BioTime’s subsidiary OncoCyte Corporation will provide an update on development of the Company’s PanC-Dx™ family of cancer diagnostic products. Dr. Wagner will describe genomic and proteomic technology developed at OncoCyte that forms the basis of these products. His talk will include information on plans for clinical trials of PanC-Dx™ in breast cancer and bladder cancer screening and new planned clinical trial in mammography patients and the recently announced lung cancer study being conducted with The Wistar Institute.
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.